Clinical Trials
14 trialsNCT01044745 2023-09-06
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
Phase 2 Terminated
NCT04688021 2023-02-21
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting
NCT01471444 2021-12-16
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00813124 2021-02-11
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00822770 2020-10-14
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00506948 2020-09-24
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03818334 2019-02-01
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Hospital Israelita Albert Einstein
Phase 2/3 Recruiting
NCT02877082 2018-04-30
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
Phase 2 Terminated
NCT00133367 2016-07-25
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Massachusetts General Hospital
Phase 2 Completed
NCT01390402 2016-02-03
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00088543 2015-03-18
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
Sanofi
Phase NA Completed
NCT00720629 2014-07-18
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00679536 2014-01-23
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Unknown